Novo Nordisk: First Phase 3 Trial With N8-GP Shows Positive Results

(RTTNews) - Novo Nordisk (NVO) announced the completion of pathfinder 2, the first phase 3 trial with long-acting recombinant factor VIII, N8-GP (turoctocog alfa pegol) for haemophilia A patients. The company said the results show that N8-GP has the potential to reduce the burden of treatment decreasing the number of intravenous infusions while achieving strong results in terms of efficacy and safety for people with haemophilia A.

Pathfinder 2 is a multi-national trial evaluating safety and efficacy of N8-GP, when administered for prophylaxis and on-demand treatment in patients with haemophilia A, who are 12 years or older.

Novo Nordisk is expecting the remaining trials in the pathfinder programme to be finalised within the next 12 months.